SEARCH

SEARCH BY CITATION

References

  • 1
    Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5: 118-124.
  • 2
    Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, et al. PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011; 17: 528-538.
  • 3
    Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1-S9.
  • 4
    Carrion JA, Fernandez-Varo G, Bruguera M, Garcia-Pagan JC, Garcia-Valdecasas JC, Perez-Del-Pulgar S, et al. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology 2010; 138: 147-158.
  • 5
    Vergniol J, Foucher J, Terrebonne E, Bernard PH, le Bail B, Merrouche W, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970-1979.
  • 6
    Adebajo CO, Talwalkar JA, Poterucha JJ, Kim WR, Charlton MR. Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. Liver Transpl 2012; 18: 323-331.
  • 7
    Berenguer M, Aguilera V, Rubin A, Ortiz C, Jimenez M, Prieto M. Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy. J Hepatol 2012; 56: 1310-1316.
  • 8
    Crespo G, Carrion JA, Coto-Llerena M, Marino Z, Lens S, Perez-Del-Pulgar S, et al. Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol; doi:10.1007/s00535-012-0680-2.
  • 9
    Berenguer M, Ortiz-Canto C, Abellan JJ, Aguilera V, Rubin A, Prieto M, et al. Hepatitis C virus viral kinetics during alpha-2a or alpha-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes. J Clin Virol 2012; 53: 231-238.
  • 10
    Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6: 1586-1599.
  • 11
    Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27.
  • 12
    Mantry PS, Hassett FNP, Weinstein J, Mubarak A, Madani B, Nazario H, et al. Triple therapy using telaprevir in the treatment of hepatitis C recurrence after liver transplantation: an early single center experience. Paper presented at: HEP DART 2011; December 4–8, 2011; Koloa, HI.
  • 13
    Burton JR, O'Leary JG, Verna EC, Lai JC, Everson GT, Trotter JF, et al. A multicenter study of protease inhibitor-triple therapy in HCV-infected liver transplant recipients: report from the CRUSH-C group. Hepatology 2012; 56.
  • 14
    Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, Demicco M, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet; doi:10.1016/S0140–6736(13)60247-0.
  • 15
    Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44.
  • 16
    Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson D, Zeuzem S, et al. 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR12 rates (observed data) of 99% in treatment-native patients and 93% in prior null responders with HCV genotype 1 infection. Paper presented at: 63rd Annual Meeting of the American Association for the Study of Liver Diseases; November 9–13, 2012; Boston, MA. Abstract LB-1 2012.
  • 17
    Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30-34.
  • 18
    Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92: 1453-1457.
  • 19
    Berenguer M, Prieto M, Cordoba J, Rayon JM, Carrasco D, Olaso V, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998; 28: 756-763.
  • 20
    Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases liver transplantation database. Liver Transpl Surg 1999; 5: S107-S114.
  • 21
    Berenguer M, Aguilera V, Prieto M, San Juan F, Rayon JM, Benlloch S, et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006; 44: 717-722.
  • 22
    Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282-1288.
  • 23
    Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007; 13: 21-29.
  • 24
    Irish WD, Arcona S, Bowers D, Trotter JF. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant 2011; 11: 1676-1685.
  • 25
    Bahra M, Neumann UI, Jacob D, Puhl G, Klupp J, Langrehr JM, et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. Am J Transplant 2005; 5: 406-411.
  • 26
    McKenna GJ, Trotter JF, Klintmalm E, Onaca N, Ruiz R, Jennings LW, et al. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant 2011; 11: 2379-2387.
  • 27
    Watt KD, Dierkhising R, Heimbach JK, Charlton MR. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl 2012; 18: 1029-1036.